Trials / Withdrawn
WithdrawnNCT05961696
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To find a recommended dose of mosunetuzumab that can be given to patients with ALL.
Detailed description
Primary Objectives: --To assess the safety of mosunetuzumab in patients with R/R B-ALL Secondary Objectives: --To assess rate of CR/CRi, duration of response (DOR), progression-free survival (PFS) and overall survival (OS) of mosunetuzumab in patients with R/R B-ALL
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mosunetuzumab | Subcutaneous (SQ or Sub-Q) injection under the skin |
Timeline
- Start date
- 2023-07-05
- Primary completion
- 2023-10-03
- Completion
- 2023-10-03
- First posted
- 2023-07-27
- Last updated
- 2023-10-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05961696. Inclusion in this directory is not an endorsement.